| Company Name: |
MQ (shanghai) Pharmaceuticals Co., Ltd.
|
| Tel: |
13761635123 |
| Email: |
1014988033@qq.com |
| Products Intro: |
Product Name:9-Ethyl-3-(1-(4-methoxyphenyl)-4,5-bis(4-(4-methylpiperazin-1-yl)phenyl)-1H-imidazol-2-yl)-9H-carbazole
CAS:2223019-53-0
Purity:＞95% Package:1G，5G
|
IZCZ-3 manufacturers
- IZCZ-3
-
- $1610.00 / 50mg
-
2025-08-21
- CAS:2223019-53-0
- Min. Order:
- Purity:
- Supply Ability: 10g
- IZCZ-3
-
- $1610.00 / 50mg
-
2025-07-20
- CAS:2223019-53-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| Product Name: | IZCZ-3 | | Synonyms: | IZCZ-3;9H-Carbazole, 9-ethyl-3-[1-(4-methoxyphenyl)-4,5-bis[4-(4-methyl-1-piperazinyl)phenyl]-1H-imidazol-2-yl]-;IZCZ 3,IZCZ3;9-Ethyl-3-(1-(4-methoxyphenyl)-4,5-bis(4-(4-methylpiperazin-1-yl)phenyl)-1H-imidazol-2-yl)-9H-carbazole;9-Ethyl-3-(1-(4-methoxyphenyl)-4,5-bis(4-(4-methylpiperazin-1-yl)phenyl)-1H-imidazol-2-yl)-9H-carbazole , IZCZ-3 | | CAS: | 2223019-53-0 | | MF: | C46H49N7O | | MW: | 715.93 | | EINECS: | | | Product Categories: | | | Mol File: | 2223019-53-0.mol |  |
| | IZCZ-3 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 5 mg/mL (6.98 mM; ultrasonic and warming and heat to 80°C) | | form | Solid | | color | Off-white to pink |
| | IZCZ-3 Usage And Synthesis |
| Uses | IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity[1]. | | Biological Activity | IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity[1].
IZCZ-3 (2.1 μM-15.9 μM; 24 hours) significantly inhibits SiHa, HeLa, Huh7, and A375 cancer cell proliferation (IC50s of 3.3, 2.1，4.1, and 4.2 μM, respectively). IZCZ-3 induces only weak growth inhibition in the BJ fibroblasts (IC50=15.9 μM) and mouse mesangial cells (IC50=15.6 μM), suggesting that IZCZ-3 is more effective against cancer cells than against c-MYC-independent normal cells[1]. IZCZ-3 (0-5 μM; 12 hours) induces an apparent accumulation of cells in the G0/G1 phase in SiHa cells in a dose-dependent manner[1].
IZCZ-3 (20, 10, and 5 mg/kg; intraperitoneally; every other day for 24 days) inhibits tumor growth in BALB/c nude mice with SiHa human cervical squamous cancer xenograft[1]. | | in vivo | IZCZ-3 (20, 10, and 5 mg/kg; intraperitoneally; every other day for 24 days) inhibits tumor growth in BALB/c nude mice with SiHa human cervical squamous cancer xenograft[1]. | Animal Model: | BALB/c nude mice (5 weeks old) bearing SiHa human cervical squamous cancer xenograft model[1] | | Dosage: | 20, 10, and 5 mg/kg | | Administration: | Treated intraperitoneally; every other day for 24 days | | Result: | Treatment with 20, 10, and 5 mg/kg resulted in a significant reduction in tumor weight with tumor growth inhibition (TGI) of 69%, 64%, and 57%, respectively. Displayed time-dependent inhibition of tumor growth. |
| | References | [1]. Hu MH, et al. Discovery of a New Four-Leaf Clover-Like Ligand as a Potent c-MYC Transcription Inhibitor Specifically Targeting the Promoter G-Quadruplex. J Med Chem. 2018 Mar 22;61(6):2447-2459. |
| | IZCZ-3 Preparation Products And Raw materials |
|